BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 21984468)

  • 1. Reliability of adverse symptom event reporting by clinicians.
    Atkinson TM; Li Y; Coffey CW; Sit L; Shaw M; Lavene D; Bennett AV; Fruscione M; Rogak L; Hay J; Gönen M; Schrag D; Basch E
    Qual Life Res; 2012 Sep; 21(7):1159-64. PubMed ID: 21984468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes.
    Basch E; Jia X; Heller G; Barz A; Sit L; Fruscione M; Appawu M; Iasonos A; Atkinson T; Goldfarb S; Culkin A; Kris MG; Schrag D
    J Natl Cancer Inst; 2009 Dec; 101(23):1624-32. PubMed ID: 19920223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study.
    Basch E; Iasonos A; McDonough T; Barz A; Culkin A; Kris MG; Scher HI; Schrag D
    Lancet Oncol; 2006 Nov; 7(11):903-9. PubMed ID: 17081915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Dueck AC; Mendoza TR; Mitchell SA; Reeve BB; Castro KM; Rogak LJ; Atkinson TM; Bennett AV; Denicoff AM; O'Mara AM; Li Y; Clauser SB; Bryant DM; Bearden JD; Gillis TA; Harness JK; Siegel RD; Paul DB; Cleeland CS; Schrag D; Sloan JA; Abernethy AP; Bruner DW; Minasian LM; Basch E;
    JAMA Oncol; 2015 Nov; 1(8):1051-9. PubMed ID: 26270597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring differences in adverse symptom event grading thresholds between clinicians and patients in the clinical trial setting.
    Atkinson TM; Rogak LJ; Heon N; Ryan SJ; Shaw M; Stark LP; Bennett AV; Basch E; Li Y
    J Cancer Res Clin Oncol; 2017 Apr; 143(4):735-743. PubMed ID: 28093637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicians versus patients subjective adverse events assessment: based on patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).
    Liu L; Suo T; Shen Y; Geng C; Song Z; Liu F; Wang J; Xie Y; Zhang Y; Tang T; Zhang L; Wang W
    Qual Life Res; 2020 Nov; 29(11):3009-3015. PubMed ID: 32564293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eliciting the child's voice in adverse event reporting in oncology trials: Cognitive interview findings from the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events initiative.
    Reeve BB; McFatrich M; Pinheiro LC; Weaver MS; Sung L; Withycombe JS; Baker JN; Mack JW; Waldron MK; Gibson D; Tomlinson D; Freyer DR; Mowbray C; Jacobs S; Palma D; Martens CE; Gold SH; Jackson KD; Hinds PS
    Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27650708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival.
    Quinten C; Maringwa J; Gotay CC; Martinelli F; Coens C; Reeve BB; Flechtner H; Greimel E; King M; Osoba D; Cleeland C; Ringash J; Schmucker-Von Koch J; Taphoorn MJ; Weis J; Bottomley A
    J Natl Cancer Inst; 2011 Dec; 103(24):1851-8. PubMed ID: 22157640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials.
    Di Maio M; Gallo C; Leighl NB; Piccirillo MC; Daniele G; Nuzzo F; Gridelli C; Gebbia V; Ciardiello F; De Placido S; Ceribelli A; Favaretto AG; de Matteis A; Feld R; Butts C; Bryce J; Signoriello S; Morabito A; Rocco G; Perrone F
    J Clin Oncol; 2015 Mar; 33(8):910-5. PubMed ID: 25624439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial.
    Basch E; Wood WA; Schrag D; Sima CS; Shaw M; Rogak LJ; Kris MG; Shouery M; Bennett A; Atkinson T; Pietanza MC
    Clin Trials; 2016 Jun; 13(3):331-7. PubMed ID: 26542025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the use of the EORTC patient-reported outcome measures for improving inter-rater reliability of CTCAE ratings in a mixed population of cancer patients: study protocol for a randomized controlled trial.
    Wintner LM; Giesinger JM; Sztankay M; Bottomley A; Holzner B;
    Trials; 2020 Oct; 21(1):849. PubMed ID: 33050917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reliability and Validity of the Korean Language Version of the U.S. National Cancer Institute's Patient-Reported Outcomes Common Terminology Criteria for Adverse Events.
    Yoon J; Sim SH; Kang D; Han G; Kim Y; Ahn J; Oh D; Lee ES; Kong SY; Cho J; Mitchell SA
    J Pain Symptom Manage; 2020 May; 59(5):1082-1088.e6. PubMed ID: 32044423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acceptability of Routine Evaluations Using Patient-Reported Outcomes of Common Terminology Criteria for Adverse Events and Other Patient-Reported Symptom Outcome Tools in Cancer Outpatients: Princess Margaret Cancer Centre Experience.
    Albaba H; Barnes TA; Veitch Z; Brown MC; Shakik S; Su S; Naik H; Wang T; Liang M; Perez-Cosio A; Eng L; Mittmann N; Xu W; Howell D; Liu G
    Oncologist; 2019 Nov; 24(11):e1219-e1227. PubMed ID: 31409744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis.
    Watanabe N; Omori IM; Nakagawa A; Cipriani A; Barbui C; McGuire H; Churchill R; Furukawa TA;
    CNS Drugs; 2010 Jan; 24(1):35-53. PubMed ID: 20030418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of Concordance in Symptomatic Adverse Event Reporting by Children, Clinicians, and Caregivers: Implications for Cancer Clinical Trials.
    Freyer DR; Lin L; Mack JW; Maurer SH; McFatrich M; Baker JN; Jacobs SS; Lucas N; Withycombe JS; Tomlinson D; Villabroza KR; Waldron MK; Hinds PS; Reeve BB
    J Clin Oncol; 2022 May; 40(15):1623-1634. PubMed ID: 35294262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE.
    Mendoza TR; Dueck AC; Bennett AV; Mitchell SA; Reeve BB; Atkinson TM; Li Y; Castro KM; Denicoff A; Rogak LJ; Piekarz RL; Cleeland CS; Sloan JA; Schrag D; Basch E
    Clin Trials; 2017 Jun; 14(3):255-263. PubMed ID: 28545337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Bennett AV; Dueck AC; Mitchell SA; Mendoza TR; Reeve BB; Atkinson TM; Castro KM; Denicoff A; Rogak LJ; Harness JK; Bearden JD; Bryant D; Siegel RD; Schrag D; Basch E;
    Health Qual Life Outcomes; 2016 Feb; 14():24. PubMed ID: 26892667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of Collaborative Reviews of Electronic Patient-Reported Outcomes on the Congruence of Patient- and Clinician-Reported Toxicity in Cancer Patients Receiving Systemic Therapy: Prospective, Multicenter, Observational Clinical Trial.
    Trojan A; Leuthold N; Thomssen C; Rody A; Winder T; Jakob A; Egger C; Held U; Jackisch C
    J Med Internet Res; 2021 Aug; 23(8):e29271. PubMed ID: 34383675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-evaluation of Adjuvant Chemotherapy-Related Adverse Effects by Patients With Breast Cancer.
    Montemurro F; Mittica G; Cagnazzo C; Longo V; Berchialla P; Solinas G; Culotta P; Martinello R; Foresto M; Gallizioli S; Calori A; Grasso B; Volpone C; Bertola G; Parola G; Tealdi G; Giuliano PL; Aglietta M; Ballari AM
    JAMA Oncol; 2016 Apr; 2(4):445-52. PubMed ID: 26720497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mapping child and adolescent self-reported symptom data to clinician-reported adverse event grading to improve pediatric oncology care and research.
    McFatrich M; Brondon J; Lucas NR; Hinds PS; Maurer SH; Mack JW; Freyer DR; Jacobs SS; Baker JN; Mowbray C; Wang M; Castellino SM; Barz Leahy A; Reeve BB
    Cancer; 2020 Jan; 126(1):140-147. PubMed ID: 31553494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.